Jérôme Biollaz

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


259 publications

2017 | 2016 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | ...
 
Renal Drug Transporters and Drug Interactions.
Ivanyuk A., Livio F., Biollaz J., Buclin T., 2017/08. Clinical pharmacokinetics, 56 (8) pp. 825-892. Peer-reviewed.
Biases affecting injected doses of an experimental drug during clinical trials.
Perrottet N., Brunner-Ferber F., Grouzmann E., Spertini F., Biollaz J., Buclin T., Widmer N., 2016/07/16. Trials, 17 (1) p. 321. Peer-reviewed.
 
Pregnancy outcome following maternal exposure to pregabalin may call for concern.
Winterfeld U., Merlob P., Baud D., Rousson V., Panchaud A., Rothuizen L.E., Bernard N., Vial T., Yates L.M., Pistelli A. et al., 2016/06/14. Neurology, 86 (24) pp. 2251-2257. Peer-reviewed.
 
Biases on the administered parenteral doses of an experimental drug during phase I clinical trials
Perrottet Ries N., Brunner-Ferber F., Grouzmann E., Spertini F., Biollaz J., Buclin T., Widmer N., 2013. pp. e2-e3 dans 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Clinical Therapeutics. Peer-reviewed.
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
 
Effect of population-based screening on breast cancer mortality.
Riva C., Biollaz J., Foucras P., Junod B., Nicot P., Spinosa J.P., 2012. Lancet, 379 (9823) pp. 1296; author reply 1298.
 
Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
Fayet Mello A., Buclin T., Franc C., Colombo S., Cruchon S., Guignard N., Biollaz J., Telenti A., Decosterd L.A., Cavassini M., 2011. Journal of Antimicrobial Chemotherapy, 66 (7) pp. 1573-1581.
 
Letter to the editor response to the article of Luisa Lina Villa HPV prophylactic vaccination: the first years and what to expect from now, in press.
Spinosa J.P., Riva C., Biollaz J., 2011. Cancer Letters, 304 (1) p. 70.
 
Pharmacovigilance [Pharmacovigilance update].
Livio F., Biollaz J., Buclin T., 2011. Revue Médicale Suisse, 7 (277) pp. 71-74.
 
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Buclin T., Widmer N., Biollaz J., Decosterd L.A., 2011. Lancet Oncology, 12 (1) pp. 9-11. Peer-reviewed.
 
Evaluation of the impact of a therapeutic drug monitoring program in a Swiss University Hospital
Fernandez S., Widmer N., Buclin T., Biollaz J., Csajka C., 2010. pp. 283-284 dans ESCP-GSASA, 38th Symposium on Clinical Pharmacy, 30 years of clinical pharmacy : a bright future ahead, Pharmacy World and Science. Peer-reviewed.
 
Pharmacovigilance update [Pharmacovigilance update]
Livio F., Ivanyuk A., Biollaz J., Rothuizen L., Buclin T., 2010. Revue Médicale Suisse, 6 (232) pp. 128-131.
 
"Iatrogenicity cascade": doing harm by treating harm?
Wagner C.C., Biollaz J., Zeitlinger M., Buclin T., 2009. Wiener Medizinische Wochenschrift, 159 (1-2) pp. 53-57.
 
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
Fayet A., Béguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Günthard H.F., Buclin T., Biollaz J. et al., 2009. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 877 (11-12) pp. 1057-1069.
 
A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.
Hodel Eva Maria, Zanolari Boris, Mercier Thomas, Biollaz Jérôme, Keiser J., Olliaro P., Genton B., Decosterd Lurent-Arthur, 2009. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 877 (10) pp. 867-886.
 
Méthylphénidate et abus
Livio F., Rauber-Lüthy C., Biollaz J., Holzer L., Winterfeld U., Buclin T., 2009. Paediatrica : Bulletin der Schweizerischen Gesellschaft für Pädiatrie (SGP) = Bulletin de la Société suisse de pédiatrie (SSP), 20 (5) pp. 41-44.
 
Pharmacodynamic interaction between SSR180575 and enalapril on the blood pressure response to angiotensin-I challenges in healthy normotensive male volunteers
Livio F., Buclin T., Nussberger J., Appenzeller M., Gaud C., Duluc M.E., Pinquier J.L., Biollaz J., 2009., Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Edinburgh p. 83 dans Basic and Clinical Pharmacology and Toxicology.
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
 
Pharmacovigilance et teratovigilance 2008 [Pharmacovigilance and teratovigilance 2008]
Livio F., Ivanyuk A., Biollaz J., 2009. Revue Médicale Suisse, 5 (186) pp. 130-134.
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-23.
 
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N., Decosterd L.A., Meylan P., Pascual M., Biollaz J., Buclin T., 2009. Clinical Pharmacokinetics, 48 (6) pp. 399-418. Peer-reviewed.
 
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.
Fayet A., Béguin A., de Tejada B.M., Colombo S., Cavassini M., Gerber S., Eap C.B., Telenti A., Buclin T., Biollaz J. et al., 2008/08. Therapeutic drug monitoring, 30 (4) pp. 511-522. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008/07/16. Revue medicale suisse, 4 (165) pp. 1644-1648. Peer-reviewed.
 
Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.
Rochat B., Fayet A., Widmer N., Lahrichi S.L., Pesse B., Décosterd L.A., Biollaz J., 2008/02. Journal of mass spectrometry, 43 (6) pp. 736-52. Peer-reviewed.
 
Ces choses dont on ne parle pas... [Those words don't speak... Aprotinin and erythropoiesis stimulant agents, therapeutic use and adverse effects]
Biollaz Jérôme, Dayer Pierre, 2008. Revue Médicale Suisse, 4 (165) pp. 1635-1636.
 
Disposition of oral valganciclovir during continuous renal replacement therapy in two lung transplant recipients
Perrottet Nancy, Robatel Corinne, Meylan Pascal, Pascual Manuel, Venetz Jean-Pierre, Aubert John-David, Berger Mette M., Decosterd Laurent A., Biollaz Jerome, Buclin Thierry, 2008. p. 566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
 
Estimation de la fonction rénale par l'equation MDRD: intérêt et limites pour l'adaptation des doses de médicaments [Renal function estimation by MDRD equation: interest and limitations for drug dosing].
Livio F., Biollaz J., Burnier M., 2008. Revue Médicale Suisse, 4 (181) pp. 2596-2600.
 
Low-dose valganciclovir is efficacious and safe for prophylaxis of cytomegalovirus infection in kidney transplantation
Perrottet Nancy, Manuel Oriol, Venetz Jean-Pierre, Lamoth Frederic, Decosterd Laurent A., Buclin Thierry, Biollaz Jerome, Meylan Pascal, Pascual Manuel, 2008. pp. 565-566 dans 8th American Transplant Congress, American Journal of Transplantation. Peer-reviewed.
 
Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration.
Grouzmann E., Buclin T., Biollaz J., 2008. American Journal of Health-System Pharmacists, 65 (3) pp. 226-228. Peer-reviewed.
 
Pharmacovigilance [Pharmacovigilance update]
Livio F., Buclin T., Biollaz J., 2008. Revue Médicale Suisse, 4 (140) pp. 150-154.
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer N., Decosterd L. A., Leyvraz S., Duchosal M. A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2008. British Journal of Cancer, 98 (10) pp. 1633-1640. Peer-reviewed.
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1644-1668. Peer-reviewed.
 
Tests pharmacogénétiques: bientôt avant chaque prescription [Pharmacogenetic testing: soon before every prescription?]
Buclin T., Colombo S., Biollaz J., 2008. Revue Médicale Suisse, 4 (165) pp. 1666-1670.
 
Effect of dronedarone on renal function in healthy subjects.
Tschuppert Y., Buclin T., Rothuizen L.., Decosterd L.A., Galleyrand J., Gaud C., Biollaz J., 2007/12. British journal of clinical pharmacology, 64 (6) pp. 785-791. Peer-reviewed.
 
Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples
Perrottet N., Beguin A., Meylan P., Pascual M., Manuel O., Buclin T., Biollaz J., Decosterd L. A., 2007/06. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 852 (1-2) pp. 420-9.
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
 
Effect of dronedarone on renal function in healthy subjects.
Tschuppert Y., Buclin T., Rothuizen L.E., Decosterd L.A., Galleyrand J., Gaud C., Biollaz J., 2007. British Journal of Clinical Pharmacology, 64 (6) pp. 785-791. Peer-reviewed.
 
Gliptins.
Grouzmann E., Buclin T., Biollaz J., 2007. Lancet, 369 (9558) p. 269. Peer-reviewed.
 
Pharmacovigilance et tératovigilance
Livio F., Buclin T., Biollaz J., 2007/01. Revue médicale suisse, 3 (95) pp. 238-242.
 
Relations entre les taux plasmatiques d'imatinib et ses effets cliniques
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. dans 14es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationships between imatinib plasma levels and efficacy
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. pp. 80S dans 75. Jahresversammlung der Schweizerisches Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Étude des biais sur la dose parentérale d'un nouveau médicament lors d'un essai clinique avec profil cinétique.
Widmer N., Perrottet N., Brunner F., Biollaz J., Buclin T., 2007. pp. 81S dans 75e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
Colombo S., Buclin T., Cavassini M., Decosterd L. A., Telenti A., Biollaz J., Csajka C., 2006/11. Antimicrobial Agents and Chemotherapy, 50 (11) pp. 3801-8.
 
Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S., Telenti A., Buclin T., Furrer H., Lee B. L., Biollaz J., Decosterd L. A., 2006/06. Therapeutic Drug Monitoring, 28 (3) pp. 332-8.
 
Generiques et article 38a OPAS: quel impact? [Generic drugs and legal incentives: which impact?]
Livio F., Buclin T., Pannatier A., Biollaz J., 2006/04. Revue Médicale Suisse, 2 (61) pp. 966-9.
 
Ne pas negliger le risque de surtraitement: l'exemple des antiepiteptiques. [Risk of overtreatment: not to be neglected. The example of antiepileptic drugs]
Rothuizen L. E., Buclin T., Reichhart M., Biollaz J., 2006/04. Revue Médicale Suisse, 2 (61) pp. 976-80.
 
Prescription hors autorisation de mise sur le marche (AMM): dans l'interet de qui? [Prescription without authorization to market: in whose interest?]
Dayer P., Biollaz J., 2006/04. Revue Médicale Suisse, 2 (61) pp. 963-4.
 
Prescription de medicaments generiques: impact du nouveau systeme de prix sur les couts et les economies potentielles. [Generic drug prescribing: pilot study on the impact of the new drug pricing system on costs and potential savings]
Wasserfallen J. B., Shimia S., Biollaz J., Pannatier A., 2006/03. Revue Médicale Suisse, 2 (59) pp. 865-6, 868-71.
 
Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.
Colombo S., Béguin A., Marzolini C., Telenti A., Biollaz J., Decosterd L.A., 2006/02. Journal of Chromatography. B, 832 (1) pp. 138-143. Peer-reviewed.
 
Les bonnes pratiques dompteront-elles la recherche clinique [Will good clinical practice domesticate human research?]
Buclin T., Burnand B., Biollaz J., 2006. Revue médicale suisse, 2 (61) pp. 992-6.
 
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Colombo S., Buclin T., Décosterd L.A., Telenti A., Furrer H., Lee B.L., Biollaz J., Eap C.B. and , 2006. Clinical pharmacology and therapeutics, 80 (4) pp. 307-18. Peer-reviewed.
 
Pharmacovigitance--pharmaco-epidemiologie. [Trends in drug therapy]
Livio F., Buclin T., Biollaz J., 2006/01. Revue Médicale Suisse, 2 (48) pp. 155-9.
 
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. British journal of clinical pharmacology, 62 (1) pp. 97-112. Peer-reviewed.
 
Relations entre la pharmacocinétique de population de l'imatinib et l'alpha-1-glycoproteine acide chez des patients hémato-oncologiques
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. dans 13es Journées Franco-Suisses de Pharmacie Hospitalière.
 
Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein
Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J. et al., 2006. pp. 71S dans 74e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures
Colombo S., Buclin T., Franc C., Guignard N., Khonkarly M., Tarr P. E., Rochat B., Biollaz J., Telenti A., Decosterd L. A. et al., 2006. Antiviral Therapy, 11 (1) pp. 53-62.
 
Étude des biais sur la dose parentérale d'un nouveau médicament lors d'un essai clinique avec profil cinétique
Widmer N., Perrottet N., Brunner F., Biollaz J., Buclin T., 2006. p. 22 dans Gemeinsamer Kongress der Gesellschaft Schweizerischer Amt- und Spitalapotheker (GSASA) und Schweizerische Gesellschaft für Spitalhygiene (SGS) = Congrès annuel de la Société Suisse des Pharmaciens de l'Administration et des Hôpitaux (GSASA) et de la Société Suisse d'Hygiène Hospitalière (SSHH), GSASA Journal. Peer-reviewed.
 
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., Decosterd L. A., 2005/05. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 819 (2) pp. 259-76.
 
Debout, collegues! [Stand up, colleagues!]
Dayer P., Biollaz J., 2005/04. Revue Médicale Suisse, 1 (14) p. 931.
 
Polypathologies: faut-il tout traiter? [Multiple diseases: should we treat them all?]
Biollaz J., Buclin T., 2005/04. Revue Médicale Suisse, 1 (14) pp. 941-7.
 
Regards recents sur la barriere hemato-encephalique. [The blood-brain barrier: recent insights]
Buclin T., Biollaz J., 2005/04. Revue Médicale Suisse, 1 (14) pp. 959-63.
 
The importance of assessing the dose actually administered in pharmacokinetic trials
Buclin T., Perrottet N., Biollaz J., 2005/04. Clinical Pharmacology and Therapeutics, 77 (4) pp. 235-40.
 
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients
Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B. L., Keiser O., Biollaz J., Decosterd L., Telenti A., 2005/01. Pharmacogenetics and Genomics, 15 (1) pp. 1-5.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 116-117 dans 7th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
 
Population pharmacokinetics of imatinib in CML and GIST patients under long-term treatment
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Csajka C., Biollaz J., Buclin T., 2005. pp. 63S dans 73e Assemblée annuelle de la Société Suisse de Médecine Interne (SSMI), Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
 
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. 1981
Brunner D. B., Desponds G., Biollaz J., Keller I., Ferber F., Gavras H., Brunner H. R., Schelling J. L., 2004/12. British Journal of Clinical Pharmacology, 58 (7) pp. S778-84; discussion S785-7.
 
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction
Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., Decosterd L. A., 2004/10. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 810 (1) pp. 25-34.
 
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
Csajka C., Marzolini C., Fattinger K., Decosterd L. A., Telenti A., Biollaz J., Buclin T., 2004/09. Antimicrobial Agents and Chemotherapy, 48 (9) pp. 3226-32.
 
Bases de donnees informatiques d'interactions medicamenteuses: quel choix? [Drug interaction computer programs: which choice?]
Perrin Y., Buclin T., Biollaz J., 2004/06. Schweizerische Rundschau fur Medizin Praxis, 93 (23) pp. 991-6.
 
Le retrait d'un medicament pour raison de securite: Processus et communication. [Withdrawal of a drug from the market for safety reasons: process and communication]
Genton A., Buclin T., 2004/05. Schweizerische Rundschau fur Medizin Praxis, 93 (19) pp. 797-801.
 
Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection
Widmer N., Beguin A., Rochat B., Buclin T., Kovacsovics T., Duchosal M. A., Leyvraz S., Rosselet A., Biollaz J., Decosterd L. A., 2004/04. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 803 (2) pp. 285-292. Peer-reviewed.
 
DTC: nouvel essor pour un ancien dopant
Buclin T., Biollaz J., 2004. Médecine et Hygiène, 62 (2476) pp. 677-681.
 
Format of medical order sheet improves security of antibiotics prescription: The experience of an intensive care unit.
Wasserfallen J.B., Bütschi A.J., Muff P., Biollaz J., Schaller M.D., Pannatier A., Revelly J.P., Chiolero R., 2004. Critical Care Medicine, 32 (3) pp. 655-659. Peer-reviewed.
 
L'information sur les médicaments: un monopole des producteurs ?
Dayer P., Biollaz J., 2004. Médecine et Hygiène, 62 p. 675.
Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.
Abriel H., Schläpfer J., Keller D.I., Gavillet B., Buclin T., Biollaz J., Stoller R., Kappenberger L., 2004. Swiss Medical Weekly, 134 (47-48) pp. 685-694. Peer-reviewed.
 
Transports rénaux de médicaments : mécanismes et potentiel d'interactions
Buclin T., Biollaz J., Diézi J., 2004. Médecine et Hygiène, 62 (2476) pp. 682-692.
 
Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients
Robatel C., Decosterd L. A., Biollaz J., Eckert P., Schaller M. D., Buclin T., 2003/12. Journal of Clinical Pharmacology, 43 (12) pp. 1329-40.
 
NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios
Nyeki A., Buclin T., Biollaz J., Decosterd L. A., 2003/01. British Journal of Clinical Pharmacology, 55 (1) pp. 62-7.
 
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C., Marzolini C., Fattinger K., Décosterd L.A., Fellay J., Telenti A., Biollaz J., Buclin T., 2003. Clinical pharmacology and therapeutics, 73 (1) pp. 20-30. Peer-reviewed.
 
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery
Marzolini C., Beguin A., Telenti A., Schreyer A., Buclin T., Biollaz J., Decosterd L. A., 2002/07. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 774 (2) pp. 127-40.
 
Comparison of the efficacy and safety of two formulations of micronized progesterone (Ellios and Utrogestan) used as luteal phase support after in vitro fertilization
Germond M., Capelli P., Bruno G., Vesnaver S., Senn A., Rouge N., Biollaz J., 2002/02. Fertility and Sterility, 77 (2) pp. 313-7.
 
Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC.
Robatel C., Buclin T., Eckert P., Schaller M.D., Biollaz J., Decosterd L.A., 2002. Journal of pharmaceutical and biomedical analysis, 29 (1-2) pp. 17-33. Peer-reviewed.
 
Expérimentation humaine et essais cliniques contrôlés
Buclin T., Biollaz J., 2002. Le Fait Médical, 51 pp. 2-3.
 
Les critères de droit utilisés par les juristes pour évaluer l?adéquation de l?information au patient sont-ils médicalement valides ? A propos d?un jugement du tribunal fédéral
Wasserfallen J. B., Telenti A., Biollaz J., Crespo A., 2002. Bulletin des Médecins Suisses, 83 pp. 2778-2780.
 
Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers.
Csajka C., Buclin T., Fattinger K., Brunner H.R., Biollaz J., 2002. Clinical pharmacokinetics, 41 (2) pp. 137-52. Peer-reviewed.
 
Transplacental passage of protease inhibitors at delivery.
Marzolini C., Rudin C., Decosterd L.A., Telenti A., Schreyer A., Biollaz J., Buclin T., 2002. AIDS, 16 (6) pp. 889-893. Peer-reviewed.
 
Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients.
Csajka C., Décosterd L.A., Buclin T., Pagani J.L., Fattinger K., Bille J., Biollaz J., 2001/12. European journal of clinical pharmacology, 57 (10) pp. 723-727. Peer-reviewed.
 
Impaired absorption of rifabutin by concomitant administration of didanosine
Marzolini C., Chave J. P., Telenti A., Brenas-Chinchon L., Biollaz J., 2001/11. AIDS, 15 (16) pp. 2203-4.
 
Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability
Marzolini C., Buclin T., Decosterd L. A., Biollaz J., Telenti A., 2001/08. Therapeutic Drug Monitoring, 23 (4) pp. 394-8.
 
Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment
Nyeki A., Biollaz J., Kesselring U. W., Decosterd L. A., 2001/05. Journal of Chromatography. B, Biomedical Sciences and Applications, 755 (1-2) pp. 73-84.
 
A preliminary evaluation of the discriminative power of the monoethylglycinexylidide formation test after intravenous and oral administration of lidocaine.
Corpataux J.M., Munafo A., Buclin T., Biollaz J., Mosimann F., 2001. Transplantation proceedings, 33 (4) pp. 2557-62. Peer-reviewed.
 
Administration entérale ou parentérale : entre croyances et abus
Tamchès E., Buclin T., Biollaz J., 2001. Médecine et Hygiène, 59 (2342) pp. 833-837.
 
Diet acids and alkalis influence calcium retention in bone.
Buclin T., Cosma M., Appenzeller M., Jacquet A.F., Décosterd L.A., Biollaz J., Burckhardt P., 2001. Osteoporosis International, 12 (6) pp. 493-499.
 
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T., 2001. AIDS, 15 (1) pp. 71-75. Peer-reviewed.
 
Prostaglandines et AINS : indications et risques dans la grossesse
Rousso P., Buclin T., Biollaz J., 2001. Médecine et Hygiène, 59 (2342) pp. 845-849.
 
Rate, type, and cost of adverse drug reactions in emergency department admissions.
Wasserfallen J., Livio F., Buclin T., Tillet L., Yersin B., Biollaz J., 2001. European Journal of Internal Medicine, 12 (5) pp. 442-447.
 
Rôle du suivi thérapeutique des concentrations d'antirétroviraux dans la prise en charge des patients HIV
Marzolini C., Décosterd L. A., Buclin T., Telenti A., Biollaz J., 2001. Médecine et Hygiène, 59 (2369) pp. 2302-2305.
 
Validation of an HPLC method for the determination of urinary and plasma levels of N1-methylnicotinamide, an endogenous marker of renal cationic transport and plasma flow
Musfeld C., Biollaz J., Belaz N., Kesselring U. W., Decosterd L. A., 2001/01. Journal of Pharmaceutical and Biomedical Analysis, 24 (3) pp. 391-404.
 
Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers
Buchwalder P. A., Buclin T., Trinchard I., Munafo A., Biollaz J., 2000/10. Journal of Interferon and Cytokine Research, 20 (10) pp. 857-66.
 
Influence of hypobaric hypoxia on leptin levels in men
Tschop M., Strasburger C. J., Topfer M., Hautmann H., Riepl R., Fischer R., Hartmann G., Morrison K., Appenzeller M., Hildebrandt W. et al., 2000/06. International Journal of Obesity and Related Metabolic Disorders, 24 Suppl 2 pp. S151.
 
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction
Marzolini C., Telenti A., Buclin T., Biollaz J., Decosterd L. A., 2000/03. Journal of Chromatography. B, Biomedical Sciences and Applications, 740 (1) pp. 43-58.
 
Anti-infectieux et hémodiafiltration continue.
Buclin T., Robatel C., Vogel G., Biollaz J., 2000. pp. 799-821 dans Martin C., Gouin F. (eds.) Infections et antibiothérapie en réanimation, aux urgences et en chirurgie, Arnette Blackwell.
 
Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
Rousso P., Buclin T., Nussberger J., Brunner-Ferber F., Brunner H.R., Biollaz J., 2000. European journal of clinical pharmacology, 55 (10) pp. 749-54. Peer-reviewed.
 
La grippe: vaccination ou antiviraux
Tamchès E., Biollaz J., 2000. Pharma-Flash, 27 (4) pp. 13-16.
 
Les abus des médicaments des personnes âgées
Buclin T., Biollaz J., 2000. pp. 131-141 dans Maffli E. (eds.) L'abus de médicaments en Suisse : état des lieux et pistes pratiques, SFA-ISPA.
 
Les intoxications médicamenteuses volontaires
Buclin T., Livio F., Yersin B., Biollaz J., 2000. pp. 113-119 dans L'abus de médicaments en Suisse chap. 11, SFA-ISPA PRESS, Lausanne.
 
Problèmes courants de pharmacologie clinique. Cas No 1 : Effet indésirable
Buclin T., Rousso P., Biollaz J., 2000. Médecine et Hygiène, 58 (2299) pp. 1009-1013.
 
Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges
Buclin T., Buchwalder-Csajka C., Brunner H. R., Biollaz J., 1999/10. British Journal of Clinical Pharmacology, 48 (4) pp. 586-93.
 
Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system
Buchwalder-Csajka C., Buclin T., Brunner H. R., Biollaz J., 1999/10. British Journal of Clinical Pharmacology, 48 (4) pp. 594-604.
 
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours
Gander M., Leyvraz S., Decosterd L., Bonfanti M., Marzolini C., Shen F., Lienard D., Perey L., Colella G., Biollaz J. et al., 1999/07. Annals of Oncology, 10 (7) pp. 831-8.
 
Trace lithium in mood disorders
Dafflon M., Decosterd L. A., Biollaz J., Preisig M., Dufour H., Buclin T., 1999/07. Journal of Affective Disorders, 54 (1-2) pp. 199-203. Peer-reviewed.
 
Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography
Decosterd L. A., Cottin E., Chen X., Lejeune F., Mirimanoff R. O., Biollaz J., Coucke P. A., 1999/05. Analytical Biochemistry, 270 (1) pp. 59-68.
 
Le delegue medical: un ami sur qui compter? [The medical advisor: a friend to count on?]
Biollaz J., Buclin T., 1999/04. Schweizerische Rundschau fur Medizin Praxis, 88 (16) pp. 719-25.
 
A bioequivalence study of calcium, a drug present in normal metabolism: regulatory issues
Buclin T., Christen G., Brossard C., Poget P. N., Rousso P., Appenzeller M., Maghraoui A., Biollaz J., 1999. British Journal of Clinical Pharmacology, Supplement for the 3rd congress of the EACPT and JC p. 38.
 
Bioéquivalence de deux sels de calcium : problèmes méthodologiques
Christen G., Buclin T., Brossard C., Poget P. N., Rousso P., Appenzeller M., Maghraoui A., Biollaz J., 1999. Schweizerische Medizinische Wochenschrift, 129 pp. S105 (31S).
 
Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
Rousso P., Buclin T., Nussberger J., Décosterd L.A., La Roche S.D., Brunner-Ferber F., Brunner H.R., Biollaz J., 1999. Journal of Hypertension, 17 (3) pp. 427-437. Peer-reviewed.
 
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, on the renal hemodynamics and tubular function in healthy volunteers under high or low sodium diet
Rousso P., Buclin T., Nussberger J., Brunner-Ferber F., Brunner H. R., Biollaz J., 1999. Journal of Hypertension, 17 pp. 1-11.
 
Grossesse et vaccinations
Csajka C., Rousso P., Gysling E., Biollaz J., 1999. Médecine et Hygiène, 57 (2251) pp. 809-811.
 
Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
Rothuizen L.E., Buclin T., Spertini F., Trinchard I., Munafo A., Buchwalder P.A., Ythier A., Biollaz J., 1999. Journal of Neuroimmunology, 99 (1) pp. 131-141.
 
Les médicaments des pensionnaires d 'établissements médico-sociaux vaudois
Lucas E., Buclin T., Martin Y., Cuttelod S., Biollaz J., 1999. Schweizerische Medizinische Wochenschrift, 129 pp. S105 (33S).
 
Les transporteurs membranaires de médicaments : une cible pharmacologique séduisante
Zaman K., Buclin T., Decosterd L. A., Biollaz J., 1999. Médecine et Hygiène, 57 (2251) pp. 801-808.
 
Pharmacocinétique du meropénème chez des patients de soins intensifs sous hémodiafiltration veno-veineuse continue (CVVHDF)
Robatel C., Buclin T., Decosterd L. A., Biollaz J., Eckert P., Broccard A., Vogel G., Wauters J. P., Chio-lero R., Schaller M. D., 1999. Nephrologie, 20(5) p. 247.
 
Raised leptin concentrations at high altitude associated with loss of appetite
Tschop M., Strasburger C. J., Hartmann G., Biollaz J., Bartsch P., 1998/10. Lancet, 352 (9134) pp. 1119-20.
 
Determination of trace lithium in human erythrocytes by electrothermal atomic-absorption spectrometry with pyrocoated graphite tubes and integrated platform
Decosterd L. A., Buclin T., Dafflon M., Leeman C., Belaz N., Magnin J. L., Biollaz J., 1998/06. Journal of Pharmacy and Pharmacology, 50 (6) pp. 693-701.
 
Estimation of glomerular filtration rate by sinistrin clearance using various approaches
Buclin T., Sechaud R., Bertschi A. P., Decosterd L. A., Belaz N., Appenzeller M., Burnier M., Biollaz J., 1998/03. Renal Failure, 20 (2) pp. 267-76.
 
Specific determination of PAH and its N-acetyl metabolite by HPLC increases the accuracy and precision of PAH clearance measurements
Decosterd L. A., Belaz N., Appenzeller M., Maghraoui A., Rousso P., Buclin T., Biollaz J., 1998/03. Renal Failure, 20 (2) pp. 311-7.
 
Comparaison du propacetamol et de la morphine dans l'analgesie postoperatoire. [Comparison of propacetamol and morphine in postoperative analgesia]
Vuilleumier P. A., Buclin T., Biollaz J., 1998/02. Schweizerische Medizinische Wochenschrift, 128 (7) pp. 259-63.
 
Circadian variations of renal sodium handling in patients with orthostatic hypotension.
Pechère-Bertschi A., Nussberger J., Biollaz J., Fahti M., Grouzmann E., Morgan T., Brunner H.R., Burnier M., 1998. Kidney international, 54 (4) pp. 1276-82. Peer-reviewed.
 
Determination of trace lithium in human erythrocytes by electrothermal atomic-absorption spectrometry with pyro-coated graphite tubes and integrated platform
Decosterd L. A., Buclin T., Dafflon M., Leeman C., Bélaz N., Magnin J. L., Biollaz J., 1998. Journal of Pharmacy and Pharmacology, 50 pp. 1-10.
 
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers.
Rousso P., Buclin T., Nussberger J., Brunner-Ferber F., Brunner H.R., Biollaz J., 1998. Journal of Cardiovascular Pharmacology, 31 (3) pp. 408-417. Peer-reviewed.
Hospitalisations pour effet indésirable médicamenteux: recensement prospectif dans un Service d'urgences médicales.
Livio Françoise, Buclin Thierry, Yersin Bertrand, Maghraoui Ali, Burnand Bernard, Biollaz Jérôme, 1998. 129 (Raisons de santé ; 23), Lausanne: CHUV, Division de pharmacologie clinique : Institut universitaire de médecine sociale et préventive (IUMSP).
 
Hospitalisations pour effets indésirables médicamenteux : Recensement prospectif dans un service d'urgences médicales
Livio F, Buclin T, Yersin B, Maghraoui A, Burnand B, Biollaz J, 1998..
 
Impfungen in der Schwangerschaft
Csajka C., Biollaz J., Gysling E., 1998. Pharma-Kritik, 20 (14) pp. 53-56.
 
Méningite aseptique sur salazopyrine : une observation et revue de la littérature
Gerster J. C., Scherrer U., Biollaz J., 1998. Rhumatologie, 50 pp. 176-178.
 
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C., Decosterd L.A., Shen F., Gander M., Leyvraz S., Bauer J., Buclin T., Biollaz J., Lejeune F., 1998. Cancer Chemotherapy and Pharmacology, 42 (6) pp. 433-440.
 
Praticiens et prescription médicamenteuse économique
Buclin T., Wasserfallen J. B., Biollaz J., 1998. Médecine et Hygiène, 56 (2204) pp. 758-765.
 
Prescription médicamenteuse lors d 'épuration extrarénale continue: bases pharmacocinétiques, revue de la littérature et validation d 'une approche prédictive simple
Buclin T., Robatel C., Biollaz J., 1998. Réan Urg, 7 pp. 232-252.
 
Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment.
Scalfaro P., Chesaux J.J., Buchwalder P.A., Biollaz J., Micheli J.L., 1998. Intensive care medicine, 24 (3) pp. 247-50. Peer-reviewed.
 
Interet et limitations du concept de demi-vie d'elimination. [Importance and limitations of metabolic drug half-life]
Buclin T., Biollaz J., 1997/10. Schweizerische Rundschau fur Medizin Praxis, 86 (43) pp. 1693-7.
 
Sinistrin clearance for determination of glomerular filtration rate: a reappraisal of various approaches using a new analytical method
Buclin T., Pechere-Bertschi A., Sechaud R., Decosterd L. A., Munafo A., Burnier M., Biollaz J., 1997/08. Journal of Clinical Pharmacology, 37 (8) pp. 679-92.
 
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.
Goldberg M.R., Lo M.W., Christ D.D., Chiou R., Furtek C.I., Amit O., Carides A., Biollaz J., Piguet V., Nussberger J. et al., 1997. Clinical pharmacology and therapeutics, 61 (1) pp. 59-69. Peer-reviewed.
 
Effects of MDL 100,240 on the glomerular filtration rate and renal tubular function in healthy volunteers under high and low sodium
Rousso P., Buclin T., Décosterd L., Nussberger J., Appenzeller M., Bélaz N., La Roche S., Brunner F., Brunner H. R., Biollaz J., 1997. Clinical Pharmacology and Therapeutics, 61 p. 206.
 
Etude comparative du propacétamol et de la morphine dans l’analgésie post-opératoire
Vuilleumier P. A., Buclin T., Biollaz J., 1997. Schweizerische Medizinische Wochenschrift, S88 pp. 15S.
 
High-performance liquid chromatography of the renal blood flow marker p-aminohippuric acid (PAH) and its metabolite N-acetyl PAH improves PAH clearance measurements.
Decosterd L.A., Karagiannis A., Roulet J.M., Bélaz N., Appenzeller M., Buclin T., Vogel P., Biollaz J., 1997. Journal of chromatography. B, Biomedical sciences and applications, 703 (1-2) pp. 25-36.
 
Influence du contenu en résidus acides de la diète sur le métabolisme et l’excrétion du calcium
Cosma M., Buclin T., Appenzeller M., Jacquet A. F., Biollaz J., Burckhardt P., 1997. Schweizerische Medizinische Wochenschrift, S88 pp. 34S.
 
Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C., Buclin T., Brunner H.R., Biollaz J., 1997. Clinical pharmacokinetics, 32 (1) pp. 1-29. Peer-reviewed.
 
Quelques aspects pharmacocinétiques et pharmacodynamiques de l'utilisation des antibiotiques chez la personne âgée
Cometta A., Biollaz J., 1997. Médecine et Hygiène, 55 (2161) pp. 887-890.
 
Spectrophotometric determination of methylene blue in biological fluids after ion-pair extraction and evidence of its adsorption on plastic polymers
Bélaz-David N., Decosterd L.A., Appenzeller M., Ruetsch Y.A., Chiolero R., Buclin T., Biollaz J., 1997. European Journal of Pharmaceutical Sciences, 5 (6) pp. 335-345.
 
Determination of the polyfructosan sinistrin in biological fluids by HPLC with electrochemical detection
Sechaud R., Decosterd L. A., Pechere-Bertschi A., Biollaz J., Kesselring U. W., 1996/02. Journal of Pharmaceutical and Biomedical Analysis, 14 (4) pp. 483-90.
 
Antibiotiques aminoglycosides: administration en doses journalières uniques
Buclin T., Cometta A., Moreillon P., Biollaz J., 1996. Médecine et Hygiène, 54 (2114) pp. 841-847.
 
Base de la thérapeutique médicamenteuse
Biollaz J., Dayer P., Galeazzi R. L., Gysling E., Haefeli W. E., Lauterburg B., Meier-Abt P., Meyer U. A., Vozeh S., 1996..
 
Determination of trace lithium in biological fluids using graphite furnace atomic absorption spectrophotometry: variability of urine matrices circumvented by cation exchange solid phase extraction.
Magnin J.L., Decosterd L.A., Centeno C., Burnier M., Diezi J., Biollaz J., 1996. Pharmaceutica acta Helvetiae, 71 (4) pp. 237-246. Peer-reviewed.
 
Effects of neuropeptide Y on intrarenal hemodynamics, plasma renin activity and urinary sodium excretion in rats.
Evéquoz D., Aubert J.F., Nussberger J., Biollaz J., Diezi J., Brunner H.R., Waeber B., 1996. Nephron, 73 (3) pp. 467-72. Peer-reviewed.
 
Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Burnier M., Buclin T., Biollaz J., Nussberger J., Waeber B., Brunner H.R., 1996. Kidney international. Supplement, 55 pp. S24-9.
 
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
Delacrétaz E., Nussberger J., Biollaz J., Waeber B., Brunner H.R., 1995. Hypertension, 25 (1) pp. 14-21. Peer-reviewed.
 
De la liberté de prescritpion
Biollaz J., Buclin T., 1995. Médecine et Hygiène, 53 (2068) pp. 872-874.
 
L'approche de l'homéostasie du sodium par le dosage du lithium trace
Pechère-Bertschi A., Burnier M., Biollaz J., 1995. Médecine et Hygiène, 53 (2063) pp. 582-584.
 
Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects.
Burnier M., Hagman M., Nussberger J., Biollaz J., Armagnac C., Brouard R., Weber B., Brunner H.R., 1995. Hypertension, 25 (4 Pt 1) pp. 602-609. Peer-reviewed.
 
Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide.
Biollaz J., Munafo A., Buclin T., Gervasoni J.P., Magnin J.L., Jaquet F., Brunner-Ferber F., 1995. European Journal of Clinical Pharmacology, 47 (5) pp. 455-460. Peer-reviewed.
 
Renal sodium handling in patients with untreated hypertension and white coat hypertension
Burnier M., Biollaz J., Magnin J. L., Bidlingmeyer M., Brunner H. R., 1994/04. Hypertension, 23 (4) pp. 496-502.
 
Fractional excretion of trace lithium and uric acid in acute renal failure.
Steinhäuslin F., Burnier M., Magnin J.L., Munafo A., Buclin T., Diezi J., Biollaz J., 1994. Journal of the American Society of Nephrology, 4 (7) pp. 1429-1437. Peer-reviewed.
L'exploitation des résultats
Biollaz J., 1994. pp. 82-85 dans Girardet P., Frutiger P. (eds.) Recherche Clinique en Ambulatoire : Expériences Pédiatriques chap. 10, Médecine et Hygiène.
 
Les désordres de la balance de l'eau
Burnier M., Waeber B., Biollaz J., Brunner H.R., 1994. pp. 51-61 dans Le métabolisme électrolytique et minéral, Médecine et Hygiène.
 
Les errances de la posologie
Biollaz J., Buclin T., 1994. Médecine et Hygiène, 52 (2022) pp. 881-886.
 
Un dialopgue indispensable ou l'approche statistique
Biollaz J., 1994. pp. 55-66 dans Girardet P., Frutiger P. (eds.) La recherche clinique en ambulatoire : expériences pédiatriques chap. 7, Médecine et Hygiène.
 
Early evening nizatidine intake with a meal optimizes the antisecretory effect
Duroux P., Emde C., Bauerfeind P., Biollaz J., Armstrong D., Blum A. L., 1993/02. Alimentary Pharmacology and Therapeutics, 7 (1) pp. 47-54.
 
Le suivi therapeutique des medicaments au cabinet medical. [Follow-up drug treatment in the practitioner's office]
Munafo A., Biollaz J., 1993/02. Schweizerische Rundschau fur Medizin Praxis, 82 (7) pp. 195-201.
 
Renal effects of nimesulide in furosemide-treated subjects
Steinhauslin F., Munafo A., Buclin T., Macciocchi A., Biollaz J., 1993. Drugs, 46 Suppl 1 pp. 257-62.
 
Selective loss of optic nerve beta-tubulin in vincristine-induced blindness
Munier F., Perentes E., Herbort C. P., Uffer S., Biollaz J., 1992/08. American Journal of Medicine, 93 (2) pp. 232-4.
 
Perte des cellules ganglionnaires de la retine secondaire a la prise de vincristine. [Loss of ganglion cells in the retina secondary to vincristine therapy]
Munier F., Uffer S., Herbort C. P., Perentes E., Diamantis I., Othenin-Girard P., Grounauer P. A., Rutz H. P., Biollaz J., 1992/05. Klinische Monatsblatter fur Augenheilkunde, 200 (5) pp. 550-4.
 
Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy
Burnier M., Biollaz J., 1992/05. Clinical Pharmacokinetics, 22 (5) pp. 375-84.
 
Interet de la determination simultanee des taux sanguins de ciclosporine par methodes specifique et non specifique chez le transplante hepatique. [Value of simultaneous determination of cyclosporin blood levels using specific and nonspecific methods in liver transplantation]
Piguet V., Mosimann F., Genton A., Appenzeller M., Munafo A., Bachmann C., Biollaz J., 1992/04. Schweizerische Medizinische Wochenschrift, 122 (17) pp. 655-8.
 
La transplantation hepatique a Lausanne. [Liver transplantation in Lausanne]
Mosimann F., Genton A., Gardaz J. P., Chiolero R., Fontolliet C., Schneider P., Bachmann C., Biollaz J., Gonvers J. J., Blum A. L., 1992/02. Revue Médicale de la Suisse Romande, 112 (2) pp. 121-5.
Arzneimittelbedingte Tosdesfälle
Biollaz J., Nussberger J., Schelling J.L., 1992. pp. 135-145 dans Berg P.S. (eds.) Unerwartete Todesfälle in Klinik und Praxis, Springer.
 
Concepts pharmacologiques du traitement des insomnies
Buclin T., Baudat J., Biollaz J., 1992. Médecine et Hygiène, 50 (1930) pp. 1157-1162.
 
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
Munafo A., Christen Y., Nussberger J., Shum L.Y., Borland R.M., Lee R.J., Waeber B., Biollaz J., Brunner H.R., 1992. Clinical pharmacology and therapeutics, 51 (5) pp. 513-21. Peer-reviewed.
 
Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition.
Chave J.P., Munafo A., Chatton J.Y., Dayer P., Glauser M.P., Biollaz J., 1992. Antimicrobial Agents and Chemotherapy, 36 (5) pp. 1013-1018.
Pharmacokinetics of Boron Sulfhydryl (BSH) in patients
G. Stragliotto , A. Munafo , J. Biollaz , H. Fankhauser , 1992..
 
The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers
Munafo A., Buclin T., Tuto D., Biollaz J., 1992. European Journal of Clinical Pharmacology, 43 (4) pp. 441-3.
 
Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide.
Chatton J.Y., Munafo A., Chave J.P., Steinhäuslin F., Roch-Ramel F., Glauser M.P., Biollaz J., 1992. British Journal of Clinical Pharmacology, 34 (6) pp. 551-554.
 
Antihypertensive therapy and mobilization of renal functional reserve
Burnier M., Biollaz J., Steinhauslin F., Brouard R., Waeber B., Brunner H. R., 1991/12. Clinical and Investigative Medicine, 14 (6) pp. 581-9.
 
Prevention of arrhythmias after noncardiac thoracic operations: flecainide versus digoxin
Borgeat A., Petropoulos P., Cavin R., Biollaz J., Munafo A., Schwander D., 1991/06. Annals of Thoracic Surgery, 51 (6) pp. 964-7; discussion 967-8.
 
Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects.
Buclin T., Biollaz J., Lippa E.A., Brunner-Ferber F., van Melle G., Munafo A., Clineschmidt C., Schelling J.L., 1991. Clinical Pharmacology and Therapeutics, 49 (6) pp. 665-673.
 
Adaptation posologique : influence de l'âge ou des pathologies associées?
Biollaz J., Munafo A., Schelling J.L., 1991. Geriatrica, 4 (4) pp. 127-131.
 
Famotidine should be taken with supper : the effect of drug-meal interactions on gastric acidity and plasma famotidine levels
Margalith D., Duroux P., Bauerfeind P., Emde C., Koelz A.R., Biollaz J., Klotz U., Armstrong D., Blum A.L., 1991. European Journal of Gastroenterology and Hepatology, 3 (5) pp. 405-412.
 
L'élaboration d'un essai thérapeutique
Biollaz J., 1991. Médecine et Hygiène, 49 (1875) pp. 458-464.
 
Prescrire la théophylline en 1991
Piguet V., Munafo A-, Biollaz J., 1991. Médecine et Hygiène, 49 (1884) pp. 1169-1173.
 
Medicaments et fonction hepatique. [Drugs and liver function]
Biollaz J., Schelling J. L., 1990/08. Revue Médicale de la Suisse Romande, 110 (8) pp. 657-9.
 
Altered flecainide disposition in healthy volunteers taking quinine.
Munafo A., Reymond-Michel G., Biollaz J., 1990. European Journal of Clinical Pharmacology, 38 (3) pp. 269-273.
 
Effect of metoclopramide on angiotensins, aldosterone, and atrial peptide during hypoxia.
Vonmoos S., Nussberger J., Waeber B., Biollaz J., Brunner H.R., Leuenberger P., 1990. Journal of Applied Physiology, 69 (6) pp. 2072-2077. Peer-reviewed.
 
Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations.
Brunner H.R., Ménard J., Waeber B., Burnier M., Biollaz J., Nussberger J., Bellet M., 1990. Journal of hypertension, 8 (1) pp. 3-11; discussion 13-9. Peer-reviewed.
 
Meniere-like syndrome following epidural morphine analgesia
Linder S., Borgeat A., Biollaz J., 1989/11. Anesthesiology, 71 (5) pp. 782-3.
 
Prevention of arrhythmias by flecainide after noncardiac thoracic surgery
Borgeat A., Biollaz J., Bayer-Berger M., Kappenberger L., Chapuis G., Chiolero R., 1989/08. Annals of Thoracic Surgery, 48 (2) pp. 232-234.
 
High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serum
Munafo A., Biollaz J., 1989/05. Journal of Chromatography, 490 (2) pp. 450-7.
 
Atrial natriuretic peptide and urinary prostaglandins in man.
Benzoni D., Geoffroy J., Waeber B., Brunner H.R., Biollaz J., Sassard J., 1989. British Journal of Clinical Pharmacology, 28 (4) pp. 397-402.
 
Atrial natriuretic peptide versus angiotensin converting enzyme inhibition
Brunner H.R., Biollaz J., Nussberger J., Waeber B., 1989. pp. 55-68 dans Sonnenblick E.H., Laragh J.H., Lesch M. (eds.) New frontiers in cardiovascular therapy: Focus on angiotensin converting enzyme inhibition, Excerpta Medica.
 
Erreurs thérapeutiques fréquentes chez les personnes âgées
Steinhäuslin F., Biollaz J., 1989. Hospitalis, 59 (10) pp. 710-714.
 
Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.
Shaheen O., Biollaz J., Koshakji R.P., Wilkinson G.R., Wood A.J., 1989. Clinical Pharmacology and Therapeutics, 45 (4) pp. 439-443.
 
Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets
Arnold P., Wermeille M., Chapuy M. C., Biollaz J., Grandjean E. M., Schelling J. L., Meunier P. J., 1989. Bone, 10 (6) pp. 401-7.
 
Troubles électrolytiques d'origine médicamenteuse: aspects physiologiques et physiopathologiques
Steinhäuslin F., Biollaz J., 1989. Médecine et Hygiène, 47 (1791) pp. 1202-1213.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University